ALK and non-small cell lung carcinoma: Pre-clinical and clinical studies demonstrate that ROS1 can be efficiently inhibited by the tyrosine kinase inhibitor crizotinib [8, 9], which is approved by the FDA and EMA as a treatment for patients with advanced ALK-positive NSCLC [10, 11].